About Myovant Sciences
Myovant Sciences is a company based in Bermuda founded in 2016 was acquired by Sumitomo Pharma in October 2022. Myovant Sciences offers products and services including Drug Pipeline, Clinical Trials, and Therapeutic Products.
- Headquarter Bermuda
- Stage Public
- SectorsHealthcare
- Website myovant.com
- Social LinkedIn X
- Acquired by Sumitomo Pharma (Oct 2022)
- Legal Name Myovant Sciences Ltd.
- Annual Revenue$230.97 M (USD)289as on Mar 31, 2022
- Net Profit-$205.98 M (USD)19as on Mar 31, 2022
- EBITDA-$187.35 M (USD)28as on Mar 31, 2022
- Latest Funding Round$100M (USD), Post-IPO
Oct 2017
- InvestorsHercules Capital
& 2 more
- Acquired bySumitomo Pharma
(Oct 2022)
Products & Services of Myovant Sciences
Myovant Sciences offers a comprehensive portfolio of products and services, including Drug Pipeline, Clinical Trials, and Therapeutic Products.
Develops new drugs for various therapeutic areas
Conducts trials for innovative health treatments
Offers drugs in oncology and neurology fields
Funding Insights of Myovant Sciences
- Total Rounds 2
- Last Round Post-IPO — $100M
- First Round $50M
(Oct 2017)
- Investors Count 2
All 2 funding rounds of Myovant Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2017 | $50M | Debt – Conventional | – | – | |
| Oct 2017 | $100M | Post-IPO | – | – |
3 investors in total: 3 institutional.
Investors in Myovant Sciences
Myovant Sciences has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Hercules Capital, Sumitomo Pharma and NovaQuest Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
PE firm focused on life science and healthcare companies | – | novaquest.com | Raleigh, United States | |
R&D company focused on manufacturing drugs for multiple therapeutic areas | 1987 | sumitomo-pharma.com | Chuo City, Japan |
Investor details for Myovant Sciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Myovant Sciences
312 people are tracked at Myovant Sciences (168 in leadership, 4 in board & advisors, 140 in team).
| Name | Role | Group |
|---|---|---|
Jennifer Conti | Director - Market Access Marketing, Myfembree | Leadership |
Gretchen Kiklis | Sr Director, Program Management Operations: Program Management & Medical Affairs (pmo) | Leadership |
Michelle V. | Area Sales Director | Leadership |
Tami Baird | Senior Area Sales Director - West | Leadership |
Kristen Rimer Sichler | Regional Sales Director, Oncology | Leadership |
Jayanthi Jayapal | Regional Sales Director | Leadership |
Max Augusterfer | Vice President Of Sales, Oncology | Leadership |
Devin Cuillierrier | Associate Director, Field Sales Incentives | Leadership |
Lynne Rourke | Associate Director, Business Operations | Leadership |
Troy Leavery | Director, Strategic Accounts | Leadership |
Shannon Phillips | Director, Talent Management And Learning Operations | Leadership |
Alan Menaged | Associate Director, Commercial Reporting | Leadership |
Angela Ward | Regional Sales Director | Leadership |
Elaine Madeo | Senior Director | Leadership |
Lisa Serfass | Associate Director, Project Management T&q | Leadership |
Chris Ott | Director Quality Assurance | Leadership |
Angela Mellon | Executive Director, Head Of Clinical And Research Quality Assurance | Leadership |
Jessica Spring | Associate Director, Order To Cash | Leadership |
Akinobu Watanabe | Associate Director, Clinical Research Scientist | Leadership |
Ron Smith | Sr. Director Strategic Accounts | Leadership |
292 more people are available in the full profile.
Complete people profiles for Myovant Sciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Myovant Sciences
4 dated milestones of Myovant Sciences across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Myovant Sciences is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $50.0M.
- Exit Acquired by Sumitomo Pharma.
Latest news on Myovant Sciences
Complete news archive for Myovant Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Myovant Sciences
10 companies that operate in the same segment as Myovant Sciences (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Myovant Sciences
Myovant Sciences was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Myovant Sciences is headquartered in Bermuda.
Annual revenue of Myovant Sciences is $230.97M as on Mar 31, 2022.
Myovant Sciences is focused on developing treatment of womens health diseases and other endocrine-related disorders. Its drug pipeline includes Relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist which is being developed for the treatment of uterine fibroids (Phase 2), endometriosis (Phase 2), and prostate cancer (Phase 2); RVT-602, an oligopeptide kisspeptin analog for the treatment of female infertility.
Myovant Sciences offers Drug Pipeline, Clinical Trials, and Therapeutic Products.
Myovant Sciences has 3 investors. Key investors include Hercules Capital, Sumitomo Pharma, and NovaQuest Capital Management.
Myovant Sciences operates through Myovant Sciences Ltd..
Yes. Myovant Sciences was acquired by Sumitomo Pharma in October 2022.